Trial Profile
Comparing the cost-effectiveness of two alternative bypassing agents (aryoseven & feiba) for patients with hemophilia A complicated by an inhibitor in Iran
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Sep 2016
Price :
$35
*
At a glance
- Drugs Recombinant factor VIIa (Primary) ; Factor VIII inhibitor bypassing fraction
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Sponsors AryoGen Biopharma
- 10 Mar 2014 Status changed from recruiting to completed as reported by Iranian Registry of Clinical Trials record.
- 17 Jun 2013 New trial record